Company / SG&A Expense
Bristol Myers Squibb SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$7.3B
FY2025
5-year range
$4.9B / $8.4B
FY2021-FY2025
Trend
-13.6%
vs FY2024
Sector context
#6 of 213
Health Care
What the data says
Among 213 Health Care companies, Bristol Myers Squibb is in the bottom 3% for sg&a expense. SG&A Expense has fluctuated over the past 10 years, ranging from $4.8B in FY2019 to $8.4B in FY2024.
Based on SEC 10-K filings.
$7.3B in FY2025 with a 5-year CAGR of -1.1%. Top quartile in the Health Care sector.
Improved from $7.7B to $7.3B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -1.7%
- 5-Year CAGR
- -1.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 213This company $7.3B Sector average $722.3M
▼
+906.1% above sector average
Key checks
Key Insights
- 5-year CAGR of -1.1%, indicating a declining trend.
- In FY2025, sg&a expense decreased 13.6% year-over-year.
- Ranks #6 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.3B | -13.6% |
| FY2024 | $8.4B | +9.4% |
| FY2023 | $7.7B | +0.4% |
| FY2022 | $7.7B | +57.3% |
| FY2021 | $4.9B | -36.4% |
| FY2020 | $7.7B | +61.3% |
| FY2019 | $4.8B | -4.6% |
| FY2018 | $5.0B | +4.8% |
| FY2017 | $4.8B | -1.5% |
| FY2016 | $4.8B | -2.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026